- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04253496
Mathematic Modeling at Micro and Macroscopic Level of Primary Central Nervous System Lymphomas (PCNSL) (LOC-MODEL)
Study Overview
Status
Intervention / Treatment
Detailed Description
Primary central nervous system lymphomas (PCNSL) are extra-nodal, malignant non-Hodgkin lymphomas of diffuse large B-cell type confined to the CNS or eyes without evidence of systemic spread. PCNSL account for up to 1% of all lymphomas and 3% of primary brain tumors. Despite recent progress in PCNSL treatment, remissions are short lasting and the outcome remains poor with a minority of long-term survivors (20%). Moreover, treatments expose patients to a high risk of neurotoxicity. Even though PCNSL has been extensively studied, the pathogenic mechanisms underlying its remarkable tropism and its peculiar clinical behaviour are not well elucidated. Since 2010, the French National Institute of Cancer (INCa) has supported the creation of medical networks dedicated to rare cancers, including PCNSL (LOC network). LOC has developed a national clinical database of newly diagnosed PCNSL with a virtual tumor database to perform translational studies. Furthermore, LOC has launched several prospective trials including a phase III clinical trial (BLOCAGE - PHRC 2014) with an expected sample size of 300 patients to perform ancillary analysis. Modeling malignant extracerebral/systemic non-Hodgkin lymphoma therapy and outcome has been previously performed, however due to its peculiar anatomical and immunoprivileged microenvironment, and its specific therapeutic management, specific modeling of PCNSL is required. Interestingly, in glioblastoma, another primary brain tumor, a model prediction of expected tumor burden provided a personalized assessment of a therapy's effectiveness. Therefore, a comprehensive mechanistic view of mathematical modeling of PCNSL growth and treatment response could be used to better stratify PCNSL evolution and to predict the best treatment options. From a radiological point of view, PCNSL often display a characteristic presentation with periventricular contrast enhancing lesions. This is due to its hypercellularity, high nuclear/cytoplasmic ratio, disruption of the blood-brain barrier, and its predilection for the periventricular and superficial regions often in contact with ventricular or meningeal surface. Interestingly, some small studies suggest that the integration of radiological and high-throughput data would help to stratify the prognosis of PCNSL. In addition, MRI assesses therapeutic response but this evaluation lacks of sensitivity to detect non-enhancing lesions. Radiomics is a promising new paradigm for extending clinical imaging into the era of molecular and genomic imaging. Interesting results using MRI and molecular phenotypes have been obtained in different cancers and very recently in glioblastomas4. However, there is only some evidence suggesting that molecular phenotype of PCNSL could be related to some particular imaging morphophenotypes. Interestingly, our team has recently identified a potential molecular-radiological association between the presence of TERT promoter mutations and the localization of PCNSL within corpus callosum. Furthermore, using MRI data (macroscopic data) will be also used to explore predictors of MRI patterns in a multivariate framework, we will develop a linear modeling approach that measures the association of MRI patterns with a number of potential predictors, including expression levels on a gene-by-gene basis, driver mutations and clinical variables. Somatically acquired mutation and cytogenetic lesion will be encoded as being present/absent. We choose a linear model due to its interpretability and established statistical methods, enabling us to test which MRI morphological pattern are associated with deregulated transcripts in the presence of specific alterations after correcting for other confounding factors and other clinical variables and coexisting driver mutations. The total variance in the MRI data will be studied and dissected using data from selected driver genes, cytogenetic lesion and the most relevant principal components of MRI data will be analyzed in a Least Absolute Shrinkage and Selection Operator (LASSO) penalized model. The optimal model maximizes the explained variance R2.
We will evaluate prognosis accuracy of survival models using Harrel's C statistic, as implemented in Hmisc R package. This statistic measures the fraction of pairs of patients with concordant risk predictions, and outcome similarly to the area under the receiver operating characteristic curve. To reduce the bias of estimated risk, we will use a fivefold cross-validating scheme. In addition, we will also analyze survival impact of this multidimensional data using random forest as an alternative approach for predicting outcome and measuring variable importance. These are implemented in the randomForesetSRC R package. the preliminary results obtained on a sub sample of patient showed that the 100 patient cohort will be sufficient to build and assess the predictive values of the models we will study. Tools to integrate multiple sources data set described above for a small subset will be scaled up using all the variables available from the complete dataset: non negative matrix co-factorization and regularized generalized canonical correlation analysis.
Patient prognosis may tightly correlate with a characteristic morphological tumor phenotype on the histological level and with tumor shape, which itself may correlate with the gene expression pattern. For this reason, macro-level growth simulations with the above statistical model will be complemented by simulations with mechanistic models at the histological level, and at whole tumor level. The histological-level model will be calibrated with experiments using diffuse large B cell lymphoma (DLBCL) cell lines co-cultured with other microenvironment cells like glial cells, and with murine experiments. This model shall shed light on the mechanisms at cell level capable of explaining the observed cell proliferation and multicellular arrangement pattern.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Paris, France, 75013
- Groupe Hospitalier la Pitié Salpêtrière
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion criteria At registration
- Newly diagnosed primary cerebral lymphoma
- Age ≥60 years
- Pathology proven diagnosis or positive cytology of the CSF or vitreous
- Karnofsky Performance Status ≥40
- No evidence of systemic NHL (body CT scan, bone marrow biopsy)
- Adequate haematological, renal and hepatic function
- Calculated creatinine clearance > 40 ml/min
At randomization
- Complete response on MRI after induction chemotherapy according to the IPCG criteria (Abrey et al, 2005)
- Karnofsky Performance Status ≥40
- Adequate haematological, renal and hepatic function
Exclusion criteria
- Positive HIV serology
- Preexisting immunodeficiency (organ transplant recipient)
- Prior treatment for PCNSL
- Isolated primary intra-ocular lymphoma
- Low grade lymphoma
- Any other active primary malignancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Retrospective
|
We will use DNA and RNA tumor samples.
We will not use germline or blood DNA.
These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
|
Prospective
|
We will use DNA and RNA tumor samples.
We will not use germline or blood DNA.
These data will be combined with their magnetic resonance imaging (MRI) at different times: at diagnosis, at the end of treatment and at the progression of the disease.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival and progression-free survival modeling using MRI and NGS data in PCNSL patients.
Time Frame: 3 years
|
PCNSL characterization through the integration of radiomics, gene expression and genotyping features. Mathematic modeling of morphological phenotypes and of prognosis and chemo-sensitivity or chemo-resistance of PCNSL using MRI and NGS data. |
3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PCNSL progression modeling.
Time Frame: 3 years
|
Analysis chemo-resistance pathways and development of new therapeutic targets in PCNSL using integrative data: mouse model of PNCSL, in vitro data and radiomics analysis.
|
3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Khê HOANG-XUAN, MD, PhD, Groupe Hospitalier La Pitié Salpêtrière - AP-HP
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PRTK16149
- 2014-002597-37 (EudraCT Number)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Central Nervous System Lymphoma (PCNSL)
-
Memorial Sloan Kettering Cancer CenterBristol-Myers SquibbActive, not recruitingPrimary Central Nervous System Lymphoma (PCNSL)United States
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; China Medical University Hospital; Chang... and other collaboratorsNot yet recruitingPrimary Central Nervous System Lymphoma (PCNSL)
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
Zhengzhou UniversityRecruitingPCNSL | Survival AnalysisChina
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.Active, not recruitingPrimary Central Nervous System Lymphoma (PCNSL) | Secondary Central Nervous System Lymphoma (SCNSL)United States
-
Huiqiang HuangXian-Janssen Pharmaceutical Ltd.; Nanfang Hospital of Southern Medical University and other collaboratorsRecruitingPrimary Central Nervous System Lymphoma | Non Hodgkin Lymphoma | PCNSLChina
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingRefractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL)United States
-
OHSU Knight Cancer InstituteNational Institute of Neurological Disorders and Stroke (NINDS); National Institutes...TerminatedPrimary Central Nervous System Lymphoma (PCNSL)United States, Germany
-
Memorial Sloan Kettering Cancer CenterPharmacyclics LLC.; Janssen Biotech, Inc.RecruitingAdult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)United States
-
Mingzhi ZhangZhengzhou UniversityCompleted
Clinical Trials on Tumor samples and MRI
-
Centre Leon BerardRecruitingMetastatic Pancreatic Cancer | Advanced Pancreatic CancerFrance
-
University Hospital, BordeauxNot yet recruitingLung Neoplasms | Immunosuppression | Myeloid-Derived Suppressor CellsFrance
-
Centre Leon BerardRecruiting
-
UNC Lineberger Comprehensive Cancer CenterAmerican Society of Clinical OncologyRecruitingCarcinoma, Squamous Cell | Head and Neck NeoplasmUnited States
-
Institut Paoli-CalmettesInstitut National de la Santé Et de la Recherche Médicale, France; Beckman...Recruiting
-
Assistance Publique - Hôpitaux de ParisCompleted
-
University Hospital, BordeauxNot yet recruitingLung Neoplasm | Cancer Associated Fibroblast | Myeloid-Derived Suppressive Cells ImmunosuppressionFrance
-
Centre Francois BaclesseRecruiting
-
Institut Claudius RegaudRecruitingCervical Cancer | Head and Neck Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Anal Cancer | Cervical Intraepithelial Neoplasia 3 | Glioblastoma Multiforme of Brain StemFrance
-
H. Lee Moffitt Cancer Center and Research InstituteJames and Esther King Biomedical Research ProgramCompleted